Clinical observation of butylphthalide soft capsules combined with rosuvastatin in the treatment of patients with acute cerebral infarction and its influence on serum Lp-PLA2,IL-18,OX40L
10.19845/j.cnki.zfysjjbzz.2023.0067
- VernacularTitle:丁苯酞软胶囊联合瑞舒伐他汀治疗急性脑梗死患者的临床观察及对血清Lp-PLA2、IL-18、OX40L的影响
- Author:
Chu NAN
1
;
Danying SU
1
Author Information
1. The Fourth Affiliated Hospital of Harbin Medical University,Harbin 150000,China
- Publication Type:Journal Article
- Keywords:
Acute cerebral infarction;
Butylphthalide soft capsules;
Rosuvastatin;
Lp-PLA2;
IL-18;
OX40L
- From:
Journal of Apoplexy and Nervous Diseases
2023;40(3):266-269
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate clinical observation of butylphthalide soft capsules combined with rosuvastatin in the treatment of patients with acute cerebral infarction and its influence on serum Lp-PLA2,IL-18,OX40L. Methods From September 2021 to January 2022,we collected 100 patients with acute cerebral infarction who were admitted to the neurology ward and outpatient department of our hospital. These patients were randomly divided into two groups:the control group and the treatment group,with 50 patients in each group. The control group was given basic treatment and rosuvastatin (10 mg/time,1 time/d),while the treatment group was additionally given butylphthalide soft capsule (0.2 g/time,3 times/d). According to the National Institutes of Health Stroke Scale (NIHSS) score and Barthel Index,the degree of neurological deficit and ability of daily life of the two groups were evaluated before and 90 days after treatment,and the levels of serum Lp-PLA2,IL-18,OX40L were compared. Results The total clinical efficacies in the treatment group were 94.00%,higher than 80.00% in the control group(P<0.05). After 90 d treatment,NIHSS score and Lp-PLA2 level decreased,Barthel index increased,and the improvement in the treatment group was significantly better than those in the control group (P<0.05). The level of serum Lp-PLA2 was higher in patients with high NIHSS scores in the treatment group than in patients with low NIHSS scores. Before treatment,there were no significant differences between the two groups in NIHSS score,Barthel index,IL-18 levels,and OX40L levels. After treatment,there were also no significant differences between the two groups in IL-18 and OX40L levels (P>0.05). The incidence of adverse reactions in the two groups was 12.00% and 16.00%,respectively(P>0.05). Conclusion The combination of butylphthalide soft capsule and rosuvastatin has good efficacy and safety,which can significantly promote the recovery of neurological function,improve the ability of daily life,and reduce the level of serum Lp-PLA2.
- Full text:2024061722273640919Clinical observation of butylphthalide soft capsules combined with rosuvastatin in the treatment of patients with acute cerebral infarction and its influence on serum Lp-PLA2,IL-18,OX40L.pdf
